CMET-20. EVIDENCE OF CNS RESPONSE OF PEMBROLIZUMAB FOR LEPTOMENINGEAL CARCINOMATOSIS AT A SINGLE CELL RESOLUTION

Approximately 8% of patients with cancer develop leptomeningeal carcinomatosis (LMD). LMD is associated with approximately 4 week median survival and a paucity of treatment options beyond palliative shunting. We performed a phase II study of the PD-1 inhibitor pembrolizumab in LMD from any solid tum...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Alvarez-Breckenridge, Christopher, Prakadan, Sanjay, Lee, Eudocia, Tolaney, Sara, Nayak, Lakshmi, Lin, Nancy, Bihun, Ivanna, Chukwueke, Ugonma, Oh, Kevin, White, Michael, Gerstner, Elizabeth, Lawrence, Donald, Cohen, Justine, Giobbie-Hurder, Anita, Cahill, Daniel, Carter, Scott, Shalek, Alex, Sullivan, Ryan, Brastianos, Priscilla
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216906/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.232
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars